SCHEMBL3499989

SCHEMBL3499989

O=C(O)c1cn2cc(Br)cnc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.50
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 4/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 1/20 0.42
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
TSHR P16473 4/20 0.35
HTT P42858 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
HPGD P15428 3/20 0.33
ALOX15 P16050 3/20 0.33
HSD17B10 Q99714 1/20 0.33
HCAR2 Q8TDS4 2/20 0.32
NAPRT Q6XQN6 1/20 0.32
TDP1 Q9NUW8 2/20 0.32
GAA P10253 1/20 0.32
MCL1 Q07820 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2731255 0.98 RXFP1 (0.49) RXFP1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL23571979 0.81 PTGS1 (0.41) RXFP1KDM4EALDH1A1PTGS1PTGS2
SCHEMBL2326296 0.81 PTGS1 (0.41) RXFP1KDM4EALDH1A1PTGS1PTGS2
SCHEMBL23553891 0.79 RXFP1 (0.43) RXFP1KDM4EALDH1A1PTGS1PTGS2
SCHEMBL21004926 0.77 KDM4E (0.61) KDM4EALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL2723092 0.77 KMT2A (0.39) RXFP1KDM4EALDH1A1RAB9APTGS1
SCHEMBL23535201 0.75 RXFP1 (0.38) RXFP1KDM4EALDH1A1SMN1; SMN2PTGS1
SCHEMBL6403237 0.74 PTGS2 (0.52) KDM4EPTGS1PTGS2P4HTM
SCHEMBL23534192 0.74 KDM4E (0.44) RXFP1KDM4EALDH1A1SMN1; SMN2PTGS1
SCHEMBL23534919 0.72 RXFP1 (0.43) RXFP1KDM4EALDH1A1SMN1; SMN2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 US disclosed
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-12441730-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2025-10-14 US disclosed
CN-110475785-B Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound 富士胶片株式会社 2023-06-13 CN disclosed
US-20230114091-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-13 US disclosed
US-20230108114-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-06 US disclosed
EP-4076460-A1 PRMT5 INHIBITORS Merck Sharp & Dohme LLC (US) 2022-10-26 EP disclosed
EP-4076459-A1 PRMT5 INHIBITORS Merck Sharp & Dohme LLC (US) 2022-10-26 EP disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
WO-2021126728-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
WO-2021126728-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
WO-2021126729-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 RXFP1 90/4885KDM4E 2059/4885ALDH1A1 3047/4885
US-20230114091-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 RXFP1 2368/4885KDM4E 61/4885ALDH1A1 1341/4885
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 RXFP1 723/4885KDM4E 306/4885ALDH1A1 2476/4885
US-12441730-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 RXFP1 2368/4885KDM4E 61/4885ALDH1A1 1341/4885
US-20230108114-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 RXFP1 2526/4885KDM4E 57/4885ALDH1A1 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.